Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.56 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.56 |
| ▸ | CDK2 | P24941 | 1/20 | 0.56 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8961559 | 0.84 | TP53 (0.57) | SMN1; SMN2NPC1RAB9AMAPTTSHR | |
| SCHEMBL5198772 | 0.84 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9ACYP2C19CYP2C9 | |
| SCHEMBL10683683 | 0.84 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9AMAPTGAA | |
| SCHEMBL19357115 | 0.80 | GAA (0.88) | SMN1; SMN2NPC1RAB9AMAPTGAA | |
| SCHEMBL10748956 | 0.80 | MAPT (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19CYP2C9 | |
| SCHEMBL8867318 | 0.79 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AMAPTMEN1 | |
| SCHEMBL8867326 | 0.79 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AMAPTMEN1 | |
| SCHEMBL11177556 | 0.78 | CYP2C19 (0.77) | SMN1; SMN2NPC1RAB9ACYP2C19CYP2C9 | |
| SCHEMBL11771349 | 0.77 | GAA (0.71) | SMN1; SMN2NPC1RAB9AMAPTGAA | |
| SCHEMBL11832873 | 0.77 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017157882-A1 | SERINE BIOSYNTHETIC PATHWAY INHIBITORS | Université Catholique de Louvain (BE) | 2017-09-21 | — | — | WO | claimed |
| WO-2017157882-A1 | SERINE BIOSYNTHETIC PATHWAY INHIBITORS | Université Catholique de Louvain (BE) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017157882-A1 | SERINE BIOSYNTHETIC PATHWAY INHIBITORS | Université Catholique de Louvain (BE) | 2017-09-21 | — | — | WO | disclosed |
| US-8088752-B2 | Methods for metabolic modulation | VDF FUTURECEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090208620-A1 | Alimentary Compositions and Methods For Metabolic Modulation | VDF FUTURECEUTICALS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090203638-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | VDF FUTURECEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20070184067-A1 | Alimentary compositions and methods for metabolic modulation | VDF FUTURECEUTICALS | 2007-08-09 | — | — | US | disclosed |
| US-20070161582-A1 | Pharmaceutical compositions and methods for metabolic modulation | VDF FUTURECEUTICALS | 2007-07-12 | — | — | US | disclosed |
| WO-2005020892-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | MITOCHROMA RESEARCH, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005016268-A2 | ALIMENTARY COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | MITOCHROMA RESEARCH, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| US-4032638-A | Heterocyclic ureas | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-06-28 | — | — | US | disclosed |
| US-3973946-A | Substituted-3-phenyl ureas | E. I. DUPONT DE NEMOURS & COMPANY (US) | 1976-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161582-A1 | Pharmaceutical compositions and methods for metabolic modulation | GPR119, PRKAG2, PRKAG1 | SMN1; SMN2 4777/4885NPC1 330/4885RAB9A 2018/4885 |
| US-20090203638-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | GPR119, PRKAG2, GCKR | SMN1; SMN2 4763/4885NPC1 359/4885RAB9A 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.